Previous 10 | Next 10 |
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for P...
Since my earlier article , Neurocrine Biosciences ( NBIX ) shares have retreated quite a bit off all time highs in September 2018. The safety scare was the first major selloff on elevated volume as an increase in reported deaths caused a panic, sending shares down over 10% one day in November...
It’s still very early, but Neurocrine Biosciences ( NBIX ) might have another compelling, largely underrated, drug in NBI-74788 for congenital adrenal hyperplasia (or CAH). Although Ph IIa data does little more than work to establish proof of concept at this point, I do believe it...
Preliminary results from a Phase 2 proof-of-concept study evaluating Neurocrine Biosciences' (NASDAQ: NBIX ) NBI-74788 in adult patients with classic congenital adrenal hyperplasia (CAH) showed a positive effect. More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, ...
SAN DIEGO , March 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NBI-74788, a proprietary corticotropin-relea...
SAN DIEGO , March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Financial Officer, of Neurocrine Biosciences will present at the following investor conferences: Cowen 3...
Neurocrine Moves Into Gene Therapy Introduction Staying true to their pipeline targeting movement disorders, Neurocrine Biosciences ( NBIX ) nabbed a deal with Voyager Therapeutics ( VYGR ) for the development and commercialization rights to gene therapy programs VY-AADC for Parki...
Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its ...
The next few years are going to seriously challenge the skills of H. Lundbeck ’s ( OTCPK:HLUYY ) (LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan Luthman, as the company has to contend with serious erosion in its mature portfolio, a very weak late-stage pipeline (not t...
Axovant Sciences Ltd ( AXON ) is approaching two key catalysts which may attract the attention of the markets. When I last wrote about the company , I noted that I didn't like the decisions being made at AXON. Throughout 2019 we may begin to see if the company's risky decision, to pivot into ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...